Syneos Health (SYNH)
Healthcare · Medical - Diagnostics & Research
2 members of Congress have disclosed 3 trades in Syneos Health (SYNH) since 2022: 0 buys and 3 sales. The most recent was disclosed on Feb 24, 2023.
- Trades disclosed
- 3
- Members trading
- 2
- Buys / sells
- 0 / 3
- Reported value
- $3K–$45K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at SYNH
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
SYNH: third_quarter 2026 lobbying report
Clinical trials and research. Remote clinical trials, biomedical research & development. Business and corporate tax issues, international tax reform; issues related to research and development.
Public: Oct 20, 2026, 5:31 PM EDTOriginal source ↗SYNH: second_quarter 2026 lobbying report
Clinical trials and research. Remote clinical trials, biomedical research & development. Business and corporate tax issues, international tax reform; issues related to research and development.
Public: Jul 20, 2026, 3:25 PM EDTOriginal source ↗
Who traded SYNH
- Rep. Josh Gottheimer (D-NJ-5)0 buys · 2 sales02Feb 17, 2023
- Rep. Daniel S. Goldman (D-NY-10)0 buys · 1 sale01Feb 24, 2023
All trades
- Feb 24, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Feb 17, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Jan 23, 2023 · disclosed Feb 17, 2023 · Joint
- Jan 13, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold (partial) Syneos Health SYNH
$1K–$15K · Traded Dec 6, 2022 · disclosed Jan 13, 2023 · Joint
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.